Testing an immune drug for hard-to-treat cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests HCB101, an immune-targeting drug, to see if it is safe and can shrink certain solid tumors or non-Hodgkin lymphoma. It may help people whose cancer has returned or stopped responding to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and can sign informed consent.
- Your cancer is confirmed by lab tests (biopsy or cell sample) and is advanced/refractory, or you have non-Hodgkin lymphoma that has returned or doesn’t respond after at least two treatments.
- Your disease has at least one spot doctors can measure (for solid tumors) or can be assessed for response (for non-Hodgkin lymphoma).
- You can provide tumor tissue for testing, and you’re expected to live at least 12 weeks.
- Your health and activity are in the ECOG range 0 to 2 (not too limited).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HCB301, which targets proteins that help cancer hide from the immune system. It is for people with advanced solid tumors or classical Hodgkin lymphoma who have tried other treatments without success.
This study tests a new drug called HC006 for advanced solid tumors that no longer respond to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
This trial is testing a new drug (HC010) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe, how it works in the body, and whether it can shrink tumors.
This study tests a new treatment that takes immune cells from a small piece of your tumor, grows them in a lab, and then puts them back into your body to fight the cancer. It is for people with advanced lung, cervical, or breast cancer who have already tried standard treatments.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.